Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00536575 · ClinicalTrials.gov registry record · Phase 1
Sorafenib and Bortezomib Treatment for Relapsed or Refractory Multiple Myeloma Patients
A Phase 1 study, sponsored by SCRI Development Innovations.
- Completed
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
NCT00536575 is a Phase 1 study that has completed, run by SCRI Development Innovations. The registered enrollment target is 13 participants.
The verdict
NCT00536575, a Phase 1 study, has completed, sponsored by SCRI Development Innovations.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
Study Summary
This is a single-arm Phase I/II study of sorafenib and bortezomib with dose optimization in initial patients. The initial patients on the dose-finding portion of this study will be enrolled through a single institution. Following establishment of the Phase II dose the study will open enrollment throughout the Sarah Cannon Research Institute (SCRI) Oncology Research Consortium. The purpose of this study is to develop the combination of bortezomib (which is proven to be clinically active in patients with multiple myeloma) with sorafenib (a potent inhibitor of angiogenesis). This regimen will be developed in a schedule that is convenient for patients, and that is as minimally toxic to patients as possible.
Interventions
- DRUG Bortezomib
- DRUG Sorafenib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2007-11 |
| Est. Completion | 2010-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00536575
The ClinicalTrials.gov registry entry for NCT00536575 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SCRI Development Innovations, which has 146 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Bortezomib is the first listed.
NCT00536575 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00536575 about?
NCT00536575 is a clinical study titled "Sorafenib and Bortezomib Treatment for Relapsed or Refractory Multiple Myeloma Patients". This is a single-arm Phase I/II study of sorafenib and bortezomib with dose optimization in initial patients. The initial patients on the dose-finding portion of this study will be enrolled through a single institution. Following establishment of the Phase II dose the study will open enrollment thro...
What is the current status of trial NCT00536575?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2007-11. Estimated completion is 2010-08.
What interventions are being tested in trial NCT00536575?
The interventions under investigation include: Bortezomib (DRUG), Sorafenib (DRUG).
Who is sponsoring clinical trial NCT00536575?
This trial is sponsored by SCRI Development Innovations, which has 146 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.